Do Traders Think Affimed NV (AFMD) Can Turn Around Thursday?

Affimed NV (AFMD) stock is down 22.51% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Affimed NV has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on AFMD!

See Full AFMD Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With AFMD Stock Today?

Affimed NV (AFMD) stock is trading at $4.51 as of 9:52 AM on Thursday, Mar 14, a drop of -$0.28, or -5.74% from the previous closing price of $4.79. The stock has traded between $4.25 and $4.86 so far today. Volume today is light. So far 35,897 shares have traded compared to average volume of 85,382 shares.

More About Affimed NV

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany. Click Here to get the full Stock Report for Affimed NV stock.